Arkolith/Insider Trading/JANX/Form 4

Meyer Andrew Hollman

Chief Business OfficerJanux Therapeutics, Inc. (JANX) · full profile →Form 4 · filed Dec 3, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$110K
Net Open-Market Flow
-$110K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 1, 2025Sell(S)633$33.52$21K85K
Dec 1, 2025Sell(S)3K$32.85$89K86K
Dec 1, 2025Option exercise(M)3K$10.59$35K88K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 1, 2025Option exercise(M)3K—$0115K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001864159-25-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML